ascopubs.org

Phase I, PK, dose-finding, active controlled study of paclitaxel injection concentrate for nanodispersion (PICN) in subjects with metastatic breast cancer.

Outcomes of inflammatory versus noninflammatory T4 breast cancers in the age of taxanes and trastuzumab. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not ...
ascopubs.org

A pilot study of the individualized maximum repeatable dose (iMRD), a new dose-finding system, of weekly paclitaxel for patients with metastatic stomach cancer as second line ...

Short-course stereotactic radiotherapy with high fraction doses for advanced intra-abdominal malignancies No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the ...
Morningstar

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

This follows safety and pharmacokinetics (PK) data analysis of the single ascending dose (SAD) study launched in March. The MAD portion of this clinical study is scheduled for completion in the third ...
Nasdaq

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...